Stemming the tide of drug-resistant Neisseria gonorrhoeae: The need for an individualized approach to treatment

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 374-381

  Buono, Sean A ^a,b   Watson, Tyler D ^a   Borenstein, Lee A ^b,c   Klausner, Jeffrey D ^d   Pandori, Mark W ^e   Godwin, Hilary A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Los Angeles County Public Health Laboratory   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Antibiotic resistance; Antimicrobial susceptibility testing; Combination therapy; Gonorrhoea; Guidelines; Molecular surveillance; Nucleic acid amplification tests; Public health

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL VACCINE; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; DRUG DEVELOPMENT; DRUG SURVEILLANCE PROGRAM; GENOTYPE; GONORRHEA; HUMAN; MICROBIOLOGICAL EXAMINATION; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PUBLIC HEALTH PROBLEM; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; PERSONALIZED MEDICINE; PREVALENCE; PROCEDURES;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GONORRHEA; HUMANS; INDIVIDUALIZED MEDICINE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREVALENCE;

EID: 84922431562     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku396     Document Type: Article

References (100)

1. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366: 485-7.
2. Whiley DM, Goire N, Lahra MM et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012; 67: 2059-61.
3. Ison CA, Hussey J, Sankar KN et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16: pii 1/4 19833.
4. Hess D, Wu A, Golparian D et al. Genome sequencing of a Neisseria gonorrhoeae isolate of a successful international clone with decreased susceptibility and resistance to extended-spectrum cephalosporins. Antimicrob Agents Chemother 2012; 56: 5633-41.
5. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7: 1401-22.
6. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2: 33-42.
7. Kirkcaldy RD, Zaidi A, Hook EWet al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013; 158: 321-8.
8. De Vries HJ, Van Der Helm JJ, Schim Van Der Loeff MF et al. Multidrug-resistant Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, the Netherlands. Euro Surveill 2009; 14: pii 1/4 19330.
9. Carpenter RJ, Refugio ON, Adams N et al. Prevalence and factors associated with asymptomatic gonococcal and chlamydial infection among US Navy and Marine Corps men infected with the HIV: a cohort study. BMJ Open 2013; 3: e002775.
10. Skerlev M, Culav-Koscak I. Gonorrhea: new challenges. Clin Dermatol 2014; 32: 275-81.
11. Ndowa F, Lusti-Narasimhan M. The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity. Reprod Health Matters 2012; 20: 76-82.
12. ECDC. Gonococcal Antimicrobial Susceptibility Surveillance in Europe, 2012. http://ecdc.europa.eu/en/publications/Publications/gonococcalantimicrobial- susceptibility-surveillance-Europe-2012.pdf.
13. Public Health England. GRASP 2012 Report: The Gonococcal Resistance to Antimicrobials Surveillance Programme. http://webarchive.national archives.gov.uk/20140714084352/http://www.hpa.org.uk/webc/HPAweb File/HPAweb_C/1317140152190.
14. CDC. Sexually Transmitted Diseases Treatment Guidelines, 2010. http:// www.cdc.gov/STD/treatment/2010/STD-Treatment-2010-RR5912.pdf.
15. CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61: 590-4.
16. WHO. Guidelines for the Management of Sexually Transmitted Infections. http://apps.who.int/iris/bitstream/10665/42782/1/9241546263_eng. pdf?ua=1.
17. Speers DJ, Fisk RE, Goire N et al. Non-culture Neisseria gonorrhoeae molecular penicillinase production surveillance demonstrates the longterm success of empirical dual therapy and informs gonorrhoea management guidelines in a highly endemic setting. J Antimicrob Chemother 2014; 69: 1243-7.
18. Levy SB. Balancing the drug-resistance equation. Trends Microbiol 1994; 2: 341-2.
19. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 441-6.
20. Kerremans JJ, Verboom P, Stijnen T et al. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother 2008; 61: 428-35.
21. Jorgensen JH, Hindler JF. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis 2007; 44: 280-6.
22. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae-2014. MMWR Recomm Rep 2014; 63: 1-19.
23. Takei M, Yamaguchi Y, Fukuda H et al. Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones. J Clin Microbiol 2005; 43: 4321-7.
24. Cartwright CP, Stock F, Gill VJ. Improved enrichment broth for cultivation of fastidious organisms. J Clin Microbiol 1994; 32: 1825-6.
25. Wade JJ, Graver MA. A fully defined, clear and protein-free liquid medium permitting dense growth of Neisseria gonorrhoeae from very low inocula. FEMS Microbiol Lett 2007; 273: 35-7.
26. Wade JJ, Graver MA. A liquid medium permitting anaerobic growth of Neisseria gonorrhoeae. J Microbiol Methods 2009; 79: 364-6.
27. Ahrens K, Bradbury KJ, Bauer HM et al. Trends in the use of sexually transmitted disease diagnostic technologies in California, 1996-2003. Sex Transm Dis 2007; 34: 513-8.
28. Kirkcaldy RD, Papp J, Weinstock HS. Gonococcal Isolate Surveillance Project (GISP) Protocol. http://www.cdc.gov/std/gisp/gisp-protocol07-15-2010.pdf.
29. CDC. Sexually Transmitted Disease Surveillance 2011. Atlanta: US Department of Health and Human Services, 2012.
30. Bignell C, Fitz Gerald M. Guideline Development Group; British Association for Sexual Health and HIV UK. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011; 22: 541-7.
31. Benson PA, Hergenroeder AC. Bacterial sexually transmitted infections in gay, lesbian, and bisexual adolescents: medical and public health perspectives. Semin Pediatr Infect Dis 2005; 16: 181-91.
32. CDC. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-United States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011; 60: 873-7.
33. Bernstein KT, Marcus JL, Barry PM et al. Characteristics of males infected with common Neisseria gonorrhoeae sequence types in the Gonococcal Isolate Surveillance Project, San Francisco, California, 2009. Am J Epidemiol 2013; 178: 1289-95.
34. Buono S, Wu A, Hess DC et al. Using the Neisseria gonorrhoeae multiantigen sequence-typing method to assess strain diversity and antibiotic resistance in San Francisco, California. Microb Drug Resist 2012; 18: 510-7.
35. Grad YH, Kirkcaldy RD, Trees D et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect Dis 2014; 14: 220-6.
36. Alloba F, Alawattegama A, Jones C. Use of nucleic acid amplification tests for the detection of Neisseria gonorrhoeae: survey of genitourinary medicine clinics in England. Int J STD AIDS 2007; 18: 652-3.
37. Goire N, Sloots TP, Nissen MD et al. Protocol for the molecular detection of antibiotic resistance mechanisms in Neisseria gonorrhoeae. Methods Mol Biol 2012; 903: 319-28.
38. California Department of Public Health. Sexually Transmitted Diseases Testing in California: 2009 Clinical Laboratory Survey Summary. http://www. cdph.ca.gov/data/statistics/Documents/STD-Data-LabSurvey.pdf.
39. Dicker LW, Mosure DJ, Steece R et al. Laboratory tests used in US public health laboratories for sexually transmitted diseases, 2000. Sex Transm Dis 2004; 31: 259-64.
40. Farrell DJ, Sheedy TJ. Urinary screening for Neisseria gonorrhoeae in asymptomatic individuals from Queensland, Australia: an evaluation using three nucleic acid amplification methods. Pathology 2001; 33: 204-5.
41. McNally LP, Templeton DJ, Jin F et al. Low positive predictive value of a nucleic acid amplification test for nongenital Neisseria gonorrhoeae infection in homosexual men. Clin Infect Dis 2008; 47: e25-7.
42. Tabrizi SN, Unemo M, Limnios AE et al. Evaluation of six commercial nucleic acid amplification tests for detection of Neisseria gonorrhoeae and other Neisseria species. J Clin Microbiol 2011; 49: 3610-5.
43. Bachmann LH, Johnson RE, Cheng H et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010; 48: 1827-32.
44. Bachmann LH, Johnson RE, Cheng H et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections. J Clin Microbiol 2009; 47: 902-7.
45. Harryman L, Scofield S, Macleod J et al. Comparative performance of culture using swabs transported in Amies medium and the Aptima Combo 2 nucleic acid amplification test in detection of Neisseria gonorrhoeae from genital and extra-genital sites: a retrospective study. Sex Transm Infect 2012; 88: 27-31.
46. Whiley DM, Tapsall JW, Sloots TP. Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge. J Mol Diagn 2006; 8: 3-15.
47. Gaydos CA, Quinn TC, Willis D et al. Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens. J Clin Microbiol 2003; 41: 304-9.
48. Hamilton MS, Otto M, Nickell A et al. High frequency of competitive inhibition in the Roche Cobas AMPLICOR multiplex PCR for Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2002; 40: 4393.
49. Marlowe EM, Novak-Weekley SM, Cumpio J et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011; 49: 1621-3.
50. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
51. Low N, Unemo M, Skov Jensen J et al. Molecular diagnostics for gonorrhoea: implications for antimicrobial resistance and the threat of untreatable gonorrhoea. PLoS Med 2014; 11: e1001598.
52. Siedner MJ, Pandori M, Leon SR et al. Detection of quinolone-resistant Neisseria gonorrhoeae in urogenital specimens with the use of real-time polymerase chain reaction. Int J STD AIDS 2008; 19: 69-71.
53. Uehara AA, Amorin EL, Ferreira Mde F et al. Molecular characterization of quinolone-resistant Neisseria gonorrhoeae isolates from Brazil. J Clin Microbiol 2011; 49: 4208-12.
54. Wu A, Buono S, Katz KA et al. Clinical Neisseria gonorrhoeae isolates in the United States with resistance to azithromycin possess mutations in all 23S rRNA alleles and the mtrR coding region. Microb Drug Resist 2011; 17: 425-7.
55. Ochiai S, Ishiko H, Yasuda M et al. Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA gene, which is associated with decreased susceptibilities to oral cephalosporins. J Clin Microbiol 2008; 46: 1804-10.
56. Pandori M, Barry PM, Wu A et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009; 53: 4032-4.
57. Whiley D, Bates J, Limnios A et al. Use of a novel screening PCR indicates presence of Neisseria gonorrhoeae isolates with a mosaic penA gene sequence in Australia. Pathology 2007; 39: 445-6.
58. Unemo M, Golparian D, Nicholas R et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56: 1273-80.
59. Whiley DM, Jacobsson S, Tapsall JWet al. Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. J Antimicrob Chemother 2010; 65: 2543-7.
60. Watchirs Smith LA, Hillman R, Ward J et al. Point-of-care tests for the diagnosis of Neisseria gonorrhoeae infection: a systematic review of operational and performance characteristics. Sex Transm Infect 2012; 89: 320-6.
61. Goire N, Lahra MM, Chen M et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol 2014; 12: 223-9.
62. Campos-Outcalt D. CDC update on gonorrhea: expand treatment to limit resistance. J Fam Pract 2011; 60: 736-40.
63. Chisholm SA, Neal TJ, Alawattegama AB et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009; 64: 353-8.
64. Domeika M, Savicheva A, Sokolovskiy E et al. Guidelines for laboratory diagnosis of Neisseria gonorrhoeae infections in Eastern European countries- results of an international collaboration. Euro Surveill 2007; 12: E071206.3.
65. WHO. Global incidence and prevalence of selected curable sexually transmitted infections: 2008. Reprod Health Matters 2012; 20: 207-9.
66. Cole MJ, Unemo M, Hoffmann S et al. The European Gonococcal Antimicrobial Surveillance Programme, 2009. Euro Surveill 2011; 16: pii 1/4 19995.
67. Van de Laar M, Spiteri G. Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe. Euro Surveill 2012; 17: pii 1/4 20225.
68. Fjeldsoe-Nielsen H, Unemo M, Fredlund H et al. Phenotypic and genotypic characterization of prolyliminopeptidase-negative Neisseria gonorrhoeae isolates in Denmark. Eur J Clin Microbiol Infect Dis 2005; 24: 280-3.
69. Whiley DM, Limnios EA, Ray S et al. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007; 51: 3111-6.
70. Garcia S, Casco R, Perazzi B et al. Ciprofloxacin resistance of Neisseria gonorrhoeae according to sexual habits. Medicina (B Aires) 2008; 68: 358-62.
71. Jakopanec I, Hassfjord JJ, Nilsen O et al. A local outbreak of quinolone-resistant gonorrhoea in Norway, January 2008. Euro Surveill 2008; 13: pii 1/4 18897.
72. Mendez Ede L, Morano ST, Mollerach AS et al. Resistance surveillance of Neisseria gonorrhoeae in a hospital in Santa Fe province, Argentina: 1997-2004. Rev Argent Microbiol 2008; 40: 173-9.
73. Galarza PG, Alcala B, Salcedo C et al. Emergence of high level azithromycin-resistant Neisseria gonorrhoeae strain isolated in Argentina. Sex Transm Dis 2009; 36: 787-8.
74. Alzahrani AJ, Obeid OE, Hassan MI et al. Screening of pregnant women attending the antenatal care clinic of a tertiary hospital in eastern Saudi Arabia for Chlamydia trachomatis and Neisseria gonorrhoeae infections. Indian J Sex Transm Dis 2010; 31: 81-6.
75. Chen PL, Lee HC, Yan JJ et al. High prevalence of mutations in quinolone-resistance-determining regions and mtrR loci in polyclonal Neisseria gonorrhoeae isolates at a tertiary hospital in southern Taiwan. J Formos Med Assoc 2010; 109: 120-7.
76. Florindo C, Pereira R, Boura M et al. Genotypes and antimicrobialresistant phenotypes of Neisseria gonorrhoeae in Portugal (2004-2009). Sex Transm Infect 2010; 86: 449-53.
77. Galarza PG, Abad R, Canigia LF et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2010; 54: 1652-3.
78. Golparian D, Hellmark B, Fredlund H et al. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect 2010; 86: 454-60.
79. Huang CT, Yen MY, Wong WW et al. Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrugresistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan. Antimicrob Agents Chemother 2010; 54: 4893-5.
80. Kubanova A, Frigo N, Kubanov A et al. The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)-national resistance prevalence in 2007 and 2008, and trends during 2005-2008. Euro Surveill 2010; 15: pii=19533.
81. Aldous WK, Robertson JL, Robinson BJ et al. Rates of gonorrhea and Chlamydia in US military personnel deployed to Iraq and Afghanistan (2004-2009). Mil Med 2011; 176: 705-10.
82. Glazkova S, Golparian D, Titov L et al. Antimicrobial susceptibility/ resistance and molecular epidemiological characteristics of Neisseria gonorrhoeae in 2009 in Belarus. APMIS 2011; 119: 537-42.
83. Hughes G, Nichols T, Ison CA. Estimating the prevalence of gonococcal resistance to antimicrobials in England and Wales. Sex Transm Infect 2011; 87: 526-31.
84. Yuan LF, Yin YP, Dai XQ et al. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011; 38: 764-8.
85. Heymans R, Bruisten SM, Golparian D et al. Clonally related Neisseria gonorrhoeae isolates with decreased susceptibility to the extendedspectrum cephalosporin cefotaxime in Amsterdam, the Netherlands. Antimicrob Agents Chemother 2012; 56: 1516-22.
86. Hjelmevoll SO, Golparian D, Dedi L et al. Phenotypic and genotypic properties of Neisseria gonorrhoeae isolates in Norway in 2009: antimicrobial resistance warrants an immediate change in national management guidelines. Eur J Clin Microbiol Infect Dis 2012; 31: 1181-6.
87. Lahra MM. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian regions, 2010. Commun Dis Intell Q Rep 2012; 36: 95-100.
88. Lawung R, Cherdtrakulkiat R, Charoenwatanachokchai A et al. Antimicrobial resistance markers as a monitoring index of gonorrhoea in Thailand. Acta Microbiol Immunol Hung 2012; 59: 157-69.
89. Velicko I, Unemo M. Recent trends in gonorrhoea and syphilis epidemiology in Sweden: 2007 to 2011. Euro Surveill 2012; 17: pii 1/4 20223.
90. Hottes TS, Lester RT, Hoang LM et al. Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex Transm Dis 2013; 40: 46-51.
91. Kirkcaldy RD, Bolan GA,Wasserheit JN. Cephalosporin-resistant gonorrhea in North America. J Amer Med Assoc 2013; 309: 185-7.
92. Lewis DA, Sriruttan C, Muller EE et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporinresistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013; 68: 1267-70.
93. Gorwitz RJ, Nakashima AK, Moran JS et al. Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae-United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ 1993; 42: 29-39.
94. Walsh C. Antibiotics: Actions, Origins, Resistance. Washington, DC: ASM Press, 2003.
95. Umland B. Penicillinase-producing Neisseria gonorrhoeae. West J Med 1988; 148: 197-8.
96. Rice RJ, Aral SO, Blount JH et al. Gonorrhea in the United States 1975-1984: is the giant only sleeping? Sex Transm Dis 1987; 14: 83-7.
97. Knapp JS, Fox KK, Trees DL et al. Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg Infect Dis 1997; 3: 33-9.
98. CDC. 1993 Sexually Transmitted Diseases Treatment Guidelines. http://www.cdc.gov/mmwr/preview/mmwrhtml/00023296.htm.
99. Lind I. Antimicrobial resistance in Neisseria gonorrhoeae. Clin Infect Dis 1997; 24 Suppl 1: S93-7.
100. College of American Pathologists. HC6-A C. trachomatis and N. gonorrhoeae by Nucleic Acid Amplification: Participant Summary. Northfield, IL: CAP, 2013.